Prestige Consumer Healthcare (NYSE:PBH) Given New $100.00 Price Target at Canaccord Genuity Group

Key Points

• Canaccord Genuity Group lowered its price target for Prestige Consumer Healthcare from $105.00 to $100.00, maintaining a "buy" rating, which suggests a 52.41% upside potential from its current price.
• The company's stock price fell by 3.0% to $65.61, with a market cap of $3.24 billion and various ratings ranging from "hold" to "buy" among analysts.
• Prestige reported earnings of $0.95 per share, missing estimates and reflecting a 6.6% revenue decline year-over-year, highlighting challenges in meeting market expectations.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) had its target price dropped by equities research analysts at Canaccord Genuity Group from $105.00 to $100.00 in a report released on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's price target would indicate a potential upside of 52.51% from the company's current price.

Other equities research analysts have also recently issued research reports about the company. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of "Hold" and a consensus target price of $93.33.

Prestige Consumer Healthcare Stock Up 0.4%

PBH stock traded up $0.26 on Friday, hitting $65.57. 68,480 shares of the company's stock were exchanged, compared to its average volume of 379,378. Prestige Consumer Healthcare has a 12-month low of $62.95 and a 12-month high of $90.04. The firm has a 50 day moving average price of $78.43 and a two-hundred day moving average price of $81.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The stock has a market cap of $3.23 billion, a P/E ratio of 15.39, a price-to-earnings-growth ratio of 2.02 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%. The firm's quarterly revenue was down 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.90 earnings per share. As a group, equities research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the business. UMB Bank n.a. raised its stake in Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company's stock valued at $26,000 after buying an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company's stock valued at $26,000 after buying an additional 250 shares in the last quarter. Maseco LLP acquired a new stake in Prestige Consumer Healthcare in the second quarter valued at $27,000. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare in the first quarter valued at $38,000. Finally, Geneos Wealth Management Inc. raised its stake in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after buying an additional 269 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.